| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2018 | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. | TECHNION CITY | HAIFA | | | | ISR | R01GM081617 | The population genetics of antibiotic resistance in multi-drug environments | 000 | 11 | NIH | 7/21/2020 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $225,850 ) |
| | 2018 | 2018 | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. | TECHNION CITY | HAIFA | | | | ISR | R01GM081617 | The population genetics of antibiotic resistance in multi-drug environments | 002 | 11 | NIH | 5/28/2018 | $216,000 |
| | 2018 | 2018 | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. | TECHNION CITY | HAIFA | | | | ISR | F33GM130382 | Comparative proteomics: The KSHV Ubiquitome in Latency and Reactivation | 001 | 1 | NIH | 7/18/2018 | $9,850 |
| | 2018 | 2017 | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. | TECHNION CITY | HAIFA | | | | ISR | R01GM081617 | The population genetics of antibiotic resistance in multi-drug environments | 001 | 10 | NIH | 1/11/2018 | $213,504 |
| | 2018 | 2017 | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. | TECHNION CITY | HAIFA | | | | ISR | R01GM081617 | The population genetics of antibiotic resistance in multi-drug environments | 000 | 10 | NIH | 1/9/2018 | -$213,504 |
|
| Issue Date FY: 2017 ( Subtotal = $213,504 ) |
| | 2017 | 2017 | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. | TECHNION CITY | HAIFA | | | | ISR | R01GM081617 | The population genetics of antibiotic resistance in multi-drug environments | 000 | 10 | NIH | 4/28/2017 | $213,504 |
|
| Issue Date FY: 2014 ( Subtotal = $346,427 ) |
| | 2014 | 2014 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | SENATE BLDG, ROOM 157 | TECHNTON CITY | | | | ISR | R01GM094792 | Tuning aminoglycosides for treatment of genetic diseases | 000 | 4 | NIH | 3/19/2014 | $346,427 |
| | 2014 | 2013 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | SENATE BLDG, ROOM 157 | TECHNTON CITY | | | | ISR | R01CA106456 | Regulation of heparanase in cancer progression | 003 | 10 | NIH | 1/16/2014 | $163,342 |
| | 2014 | 2013 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | SENATE BLDG, ROOM 157 | TECHNTON CITY | | | | ISR | R01CA106456 | Regulation of heparanase in cancer progression | 002 | 10 | NIH | 1/14/2014 | -$163,342 |
| | 2014 | 2013 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | SENATE BLDG, ROOM 157 | TECHNTON CITY | | | | ISR | R01CA106456 | Regulation of heparanase in cancer progression | 001 | 10 | NIH | 12/17/2013 | $163,342 |
| | 2014 | 2013 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | SENATE BLDG, ROOM 157 | TECHNTON CITY | | | | ISR | R01CA106456 | Regulation of heparanase in cancer progression | 000 | 10 | NIH | 12/12/2013 | -$163,342 |
|
| Issue Date FY: 2013 ( Subtotal = $622,843 ) |
| | 2013 | 2013 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01GM094792 | Tuning aminoglycosides for treatment of genetic diseases | 001 | 3 | NIH | 6/25/2013 | $22,316 |
| | 2013 | 2013 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01CA106456 | Regulation of heparanase in cancer progression | 003 | 10 | NIH | 12/17/2013 | $163,342 |
| | 2013 | 2013 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01DK085226 | OXIDATION HYPOTHESIS REVISITED: HAPTOGLOBIN GENOTYPE & DIABETIC ATHEROSCLEROSIS | 000 | 5 | NIH | 7/4/2013 | $100,000 |
| | 2013 | 2013 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01DK085226 | OXIDATION HYPOTHESIS REVISITED: HAPTOGLOBIN GENOTYPE & DIABETIC ATHEROSCLEROSIS | 000 | 5 | NIH | 7/4/2013 | $28,193 |
| | 2013 | 2013 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01CA106456 | Regulation of heparanase in cancer progression | 004 | 10 | NIH | 1/14/2014 | -$163,342 |
| | 2013 | 2013 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01CA106456 | Regulation of heparanase in cancer progression | 005 | 10 | NIH | 1/16/2014 | $163,342 |
| | 2013 | 2013 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01CA106456 | Regulation of heparanase in cancer progression | 000 | 10 | NIH | 2/7/2013 | $78,196 |
| | 2013 | 2013 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01CA106456 | Regulation of heparanase in cancer progression | 001 | 10 | NIH | 7/2/2013 | $85,146 |
| | 2013 | 2013 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01CA106456 | Regulation of heparanase in cancer progression | 002 | 10 | NIH | 12/12/2013 | -$163,342 |
| | 2013 | 2013 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01GM094792 | Tuning aminoglycosides for treatment of genetic diseases | 000 | 3 | NIH | 3/14/2013 | $308,992 |
|
| Issue Date FY: 2012 ( Subtotal = $649,936 ) |
| | 2012 | 2012 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01CA106456 | Regulation of heparanase in cancer progression | 001 | 9 | NIH | 3/27/2012 | $173,769 |
| | 2012 | 2012 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01DK085226 | OXIDATION HYPOTHESIS REVISITED: HAPTOGLOBIN GENOTYPE & DIABETIC ATHEROSCLEROSIS | 000 | 4 | NIH | 7/26/2012 | $100,000 |
| | 2012 | 2012 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01DK085226 | OXIDATION HYPOTHESIS REVISITED: HAPTOGLOBIN GENOTYPE & DIABETIC ATHEROSCLEROSIS | 000 | 4 | NIH | 7/26/2012 | $32,843 |
| | 2012 | 2012 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01GM094792 | Tuning aminoglycosides for treatment of genetic diseases | 000 | 2 | NIH | 3/29/2012 | $343,324 |
| | 2012 | 2011 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | SENATE BLDG, ROOM 157 | TECHNTON CITY | | | | ISR | R01CA106456 | Regulation of heparanase in cancer progression | 000 | 8 | NIH | 3/13/2012 | $0 |
|
| Issue Date FY: 2011 ( Subtotal = $641,756 ) |
| | 2011 | 2011 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01GM094792 | Tuning aminoglycosides for treatment of genetic diseases | 000 | 1 | NIH | 3/28/2011 | $323,694 |
| | 2011 | 2011 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01GM094792 | Tuning aminoglycosides for treatment of genetic diseases | 001 | 1 | NIH | 5/2/2011 | $16,511 |
| | 2011 | 2011 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01CA106456 | Regulation of heparanase in cancer progression | 000 | 8 | NIH | 2/15/2011 | $161,230 |
| | 2011 | 2011 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01CA106456 | Regulation of heparanase in cancer progression | 001 | 8 | NIH | 5/17/2011 | $7,478 |
| | 2011 | 2011 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01DK085226 | OXIDATION HYPOTHESIS REVISITED: HAPTOGLOBIN GENOTYPE & DIABETIC ATHEROSCLEROSIS | 000 | 3 | NIH | 6/23/2011 | $100,000 |
| | 2011 | 2011 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01DK085226 | OXIDATION HYPOTHESIS REVISITED: HAPTOGLOBIN GENOTYPE & DIABETIC ATHEROSCLEROSIS | 000 | 3 | NIH | 6/23/2011 | $32,843 |
| | 2011 | 2011 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | SENATE BLDG, ROOM 157 | TECHNTON CITY | | | | ISR | R01GM094792 | Tuning aminoglycosides for treatment of genetic diseases | 002 | 1 | NIH | 7/8/2011 | $0 |
|
| Issue Date FY: 2010 ( Subtotal = $313,328 ) |
| | 2010 | 2010 | TECHNION-ISRAEL INSTITUTE OF TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | - | | ISR | R01CA106456 | Regulation of heparanase in cancer progression | 000 | 7 | NIH | 2/5/2010 | $179,143 |
| | 2010 | 2010 | TECHNION-ISRAEL INSTITUTE OF TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01DK085226 | OXIDATION HYPOTHESIS REVISITED: HAPTOGLOBIN GENOTYPE & DIABETIC ATHEROSCLEROSIS | 000 | 2 | NIH | 7/12/2010 | $34,185 |
| | 2010 | 2010 | TECHNION-ISRAEL INSTITUTE OF TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01DK085226 | OXIDATION HYPOTHESIS REVISITED: HAPTOGLOBIN GENOTYPE & DIABETIC ATHEROSCLEROSIS | 000 | 2 | NIH | 7/12/2010 | $100,000 |
| | 2010 | 2008 | TECHNION ISRAEL INSTITUTE TECHNOLOGY | SENATE BLDG, ROOM 157 | TECHNTON CITY | | | | ISR | R01CA115550 | THERAPEUTIC POTENTIAL OF TCR-LIKE RECOMBINANT ANTIBODIES | 000 | 4 | NIH | 5/12/2010 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $314,683 ) |
| | 2009 | 2009 | TECHNION-ISRAEL INSTITUTE OF TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01DK085226 | OXIDATION HYPOTHESIS REVISITED: HAPTOGLOBIN GENOTYPE & DIABETIC ATHEROSCLEROSIS | 000 | 1 | NIH | 5/1/2009 | $35,540 |
| | 2009 | 2009 | TECHNION-ISRAEL INSTITUTE OF TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | | | ISR | R01DK085226 | OXIDATION HYPOTHESIS REVISITED: HAPTOGLOBIN GENOTYPE & DIABETIC ATHEROSCLEROSIS | 000 | 1 | NIH | 5/1/2009 | $100,000 |
| | 2009 | 2009 | TECHNION-ISRAEL INSTITUTE OF TECHNOLOGY | TECHNION CITY 32000 | HAIFA | | - | | ISR | R01CA106456 | Regulation of heparanase in cancer progression | 000 | 6 | NIH | 4/28/2009 | $179,143 |
|
| Issue Date FY: 2008 ( Subtotal = $528,159 ) (Continued on the next page) |
|
